Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with CML-AP (N ¼ 137) with at least 24 months of follow-up or who discontinued early were evaluated to determine the efficacy and tolerability of nilotinib. The majority (55%) of patients achieved a confirmed hematologic response, and 31% attained a confirmed complete hematologic response on nilotinib treatment. Overall, 32% of patients achieved major cytogenetic responses (MCyR), with most being complete cytogenetic responses. Responses were durable, with 66% of patients maintaining MCyR at 24 months. The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42% of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilotinib has not changed with longer follow-up. In all, 20 (15%) patients remained on study at data cutoff. In summary, nilotinib has a manageable safety profile, and can provide favorable long-term outcomes in the pretreated CML-AP patient population for whom treatment options are limited.
INTRODUCTION
The BCR-ABL tyrosine kinase inhibitor, imatinib (Gleevec/Glivec; Novartis Pharmaceuticals Corporation, Basel, Switzerland), has significantly improved outcomes in patients with Ph þ chronic myeloid leukemia (CML). 1, 2 At diagnosis, CML typically presents in the chronic phase (CML-CP) and can progress to accelerated phase disease (CML-AP), eventually reaching blast crisis (CML-BC). 3 Indeed, most cases of CML-AP arise from CML-CP that has progressed and are not de novo CML-AP cases. Before the use of imatinib therapy, the median survival of CML-AP patients was less than 18 months. 4 A 7-year follow-up of a large, phase 2 study of CML-AP patients treated with imatinib 600 mg once daily reported a median survival of 37 months, which was associated with the achievement of complete hematologic response (CHR) or complete cytogenetic response (CCyR) on treatment. 5 It is estimated that 30 --35% of patients with CML-CP discontinue imatinib either because of toxicity or resistance, and disease progression to CML-AP is often evidenced by increased refractoriness to standard imatinib therapy. 4, 6 Resistance to imatinib develops through various mechanisms, but the acquired resistance most frequently results from point mutations in the BCR-ABL kinase domain. 7 These mutations are linked with impaired binding of imatinib to BCR-ABL, and are more frequently observed in patients who have progressed to CML-AP. 8, 9 Until recently, few treatment options existed for imatinibresistant or -intolerant CML-AP patients.
Nilotinib (Tasigna; Novartis) is a rationally designed tyrosine kinase inhibitor that targets the BCR-ABL kinase with greater potency and specificity compared with imatinib. 10 --12 Preclinical activity of nilotinib was demonstrated in imatinib-resistant cells carrying either KD-mutations or clonal evolution. 13, 14 A phase 1, dose-escalation study, including patients with imatinib-resistant Ph þ CML (the majority of whom were patients with Ph þ CML-AP), found that nilotinib treatment resulted in significant hematologic responses and cytogenetic responses in all phases of CML. 15 The primary objective of this single-treatment arm, open-label phase 2 study was to determine the efficacy of nilotinib in patients with Ph þ CML-AP who are resistant or intolerant to imatinib therapy. Results from this study were previously reported for patients with at least 6 months of follow-up or who discontinued early (N ¼ 119). 16 The results presented here include patients with at least 24 months of follow-up or who discontinued early (N ¼ 137).
PATIENTS AND METHODS

Patient population
As previously described, 16 patients with Ph þ CML-AP at least 18 years of age with imatinib resistance or intolerance were eligible for this study. AP was defined as never-in-BC before starting the treatment, with one or more of the following criteria present within 4 weeks before the beginning treatment: 415% but o30% blasts in blood or bone marrow, X30% blasts plus promyelocytes in peripheral blood or bone marrow (provided that o30% blasts are present in bone marrow), peripheral basophils X20%, or thrombocytopenia p100 Â 10 9 /l unrelated to therapy. Resistance was defined as no CHR at or after 3 months; no minimal cytogenetic response by 6 months; no major cytogenetic response (McyR) by 12 months; loss of CHR; loss of minor cytogenetic response; loss of MCyR or CCyR; or development of clonal evolution. Imatinib intolerance was defined as discontinuation due to a grade 3/4 imatinib-related adverse event (AE), despite optimal supportive care, or due to a persistent grade 2 imatinibrelated AE, despite optimal supportive care, which persisted for more than 1 month or recurred more than three times with imatinib dose reduction. Patients with imatinib intolerance in this study also had an element of resistance because they were defined as patients not having achieved MCyR at any point of time on imatinib therapy.
Mutational analysis
Mutational analyses of the BCR-ABL kinase domain were performed at baseline (before the start of nilotinib therapy) and during nilotinib therapy. For patients who had baseline mutations, subsequent mutational analyses were performed every 3 months until the mutations were undetectable. For those patients without baseline mutations, mutational assays were only performed when there was a significant rise in the BCR-ABL transcript levels measured by real-time quantitative-PCR or at study discontinuation or at the time of progression. RNA was reverse transcribed and the BCR-ABL kinase domain (residues 230 --490) amplified, and mutations were identified by direct sequencing, enabling detection of more than 20 --30% of clones. The criterion for a significant rise of BCR-ABL transcripts ranged between greater than two-and five-fold according to the level of residual disease. BCR-ABL transcript levels from five participating laboratories were converted to IS as previously described. 17 --20 Objectives and trial design
The objectives of this phase 2, single-treatment arm, open-label study were to determine the rates of confirmed hematologic response (HR), and secondarily to characterize the rates of MCyR, CCyR, major molecular response and overall survival, and the safety profile of nilotinib in patients with CML-AP resistant to or intolerant of imatinib therapy. Efficacy analysis included all patients enrolled. At the time of this analysis, all patients had at least 24 months of follow-up or had discontinued early. Definitions of response have been previously described. 16 Duration of response was defined as time from the date of first occurrence of the response to the date of discontinuation due to progression as assessed by the investigator (recurrence of CML-AP after HR, transformation to CML-BC) or death. Progression-free survival was defined as the time from the start of nilotinib treatment to the earliest date of progression, discontinuation due to progression (as assessed by the investigator) or death from any cause on nilotinib therapy. Survival was calculated from the start of nilotinib treatment to death due to any cause. All time-to-event analyses were performed using Kaplan --Meier methods and are represented by Kaplan --Meier curves. Safety analysis included all patients who received at least one dose of nilotinib. Nilotinib was administered at a dose of 400 mg orally twice daily. This study was conducted in accordance with the Declaration of Helsinki and all patients gave written informed consent according to institutional guidelines.
RESULTS
Patient demographics and disposition
Patients with Ph þ CML-AP (N ¼ 137, 109 (80%) imatinib resistant, 27 (20%) imatinib intolerant and 1 (o1%) unknown) and a minimum of 24 months of follow-up or who discontinued early were included in this analysis. The median age was 57 years ( Table 1 ). The median duration of CML was 71 months and the median duration of prior imatinib therapy was 28 months. A total of 79% of patients had prior imatinib doses X600 mg/day and 45% had prior imatinib doses of X800 mg/day.
In all, 15% of patients (20/137) remained on study, whereas 85% (117/137) discontinued by the data cutoff (Table 2) . Discontinuation due to disease progression occurred in 44% (60/137) of patients. Only 10% of patients discontinued nilotinib because of drug-related AEs. Efficacy Overall, confirmed HR was achieved in 55% of patients, with 31% reporting achievement of a confirmed CHR (30% for imatinibresistant patients and 37% for imatinib-intolerant patients). Those with HR were most often not characterized as CHR because of platelet counts being o100 Â 10 9 /l. The median time to first HR among responders was 1 month. The rate of MCyR was 32% overall (30% for imatinib-resistant patients and 41% for imatinibintolerant patients; Figure 1 ). The median time to MCyR among responders was 2.8 months. A CCyR was achieved by 21% of Two patients had peripheral blood blasts X30% (one with 33% and one with 42%).
patients (19% for imatinib-resistant patients and 30% for imatinibintolerant patients).
Hematologic and cytogenetic responses were durable, with an estimated 49% and 66% of responders maintaining an HR and MCyR at 24 months, respectively (Figures 2a and b) . Median duration of HR was 21.5 months (range, 2.2 --37.2 months). The median duration of MCyR had not been reached at the time of data cutoff.
Among the 109 patients, 93 imatinib-resistant and 16 imatinibintolerant patients, who had blood BCR-ABL transcript data available post baseline, 12 (11%) achieved major molecular response (MMR). The median time to MMR among responders was 11 months (range, 2 --17 months), and the median time to the lowest level of BCR-ABL transcript was 12 months (range, 2 --24 months). Of those patients who achieved a CCyR, 38% (11 of 29 patients) also achieved an MMR. The median time to progression was 16 months and the estimated progression-free survival at 24 months was 33%. Overall, an estimated 70% of patients were alive at 24 months (Figure 2c ).
Baseline BCR-ABL mutations and responses A total of 23 different types of mutations affecting 19 amino-acid residues were identified in 109 imatinib-resistant or -intolerant patients who had baseline BCR-ABL mutation data available (61% (57/93) resistant patients and 13% (2/16) intolerant patients). Multiple mutations were detected in 8% (9/109) patients. Nilotinib-sensitive baseline mutations (in vitro IC 50 p150 nM) 21 and mutations with unknown in vitro sensitivity were observed in 33% (36/109) of patients, whereas 16% (17/109) of patients had less-sensitive mutations (Y253H, E255K/V, F359C/V). These lesssensitive mutations not only have higher in vitro IC 50 values (4150 nM) but also have previously been identified in imatinibresistant patients with CML-CP to have less favorable response to nilotinib therapy. 21 Six imatinib-resistant patients had T315I at baseline. While on treatment with nilotinib, new mutations were detected in 20/57 (35%) of imatinib-resistant patients with baseline mutations (7/57 with T315I) and 11/36 (31%) imatinibresistant patients without baseline mutations (1/36 patients with T315I).
Overall, clinically meaningful hematologic, cytogenetic, and molecular responses were observed in Ph þ CML-AP patients with imatinib resistance without baseline mutations and in those harboring mutations with high in vitro sensitivity to nilotinib (Table 3) . However, lower response rates for all three response measures were observed in patients with mutations at Y253H, E255K/V, and F359C/V, all known to be less sensitive to nilotinib therapy.
Confirmed HR with nilotinib therapy was achieved by 24 months in 51% (29/57) and 56% (20/36) in patients with and without detectable baseline mutations, respectively, during nilotinib therapy (Table 3 ). In patients with sensitive mutations to nilotinib in vitro and patients with mutations of unknown IC 50 , 79% (19/24) and 40% (4/10) achieved confirmed HR, respectively, compared with only 24% (4/17) of patients with less-sensitive mutations.
MCyR was achieved in 19% (11/57) and 39% (14/36) of the imatinib-resistant patients with and without baseline mutations, respectively, whereas 14% (8/57) of patients with mutations and 28% (10/36) of patients without mutations achieved CCyR (Table 3) . Of those patients with sensitive baseline mutations or mutations of unknown sensitivity, 33% (8/24) and 10% (1/10) achieved MCyR, compared with 6% (1/17) of patients with lesssensitive mutations. Similarly, 29% (7/24) of patients with sensitive baseline mutations and 10% (1/10) of patients with mutations of unknown sensitivity achieved CcyR; however, no patient with lesssensitive mutations achieved a CCyR. Of the 93 imatinib-resistant patients with CML-AP with available baseline mutation data, 76 patients were assessed for MMR (Table 3) . Overall, 8% (4/49) of patients with baseline mutations versus 11% (3/27) of patients without baseline mutations achieved MMR during nilotinib therapy. In patients with sensitive mutations, less-sensitive mutations and mutations of unknown sensitivity , 14% (3/22), 0 and 11% (1/9) achieved MMR, respectively.
Safety/tolerability
The median duration of nilotinib therapy was 264 days (range, 2 --1160 days), and the median dose delivered was 780 mg/day (range, 150 --1149 mg/day), which was close to the planned dose of 800 mg/day. Dose interruptions were necessary for 55% of patients with a short median cumulative duration of 23 days (range, 4 --23 days) and 40% of patients required a dose reduction.
With at least 24 months of follow-up, the safety profile of nilotinib in patients with CML-AP was consistent with the safety profile with at least 6 months of follow-up (Table 4) . 16 The most frequent drug-related non-hematologic AEs reported were rash, pruritus and fatigue. 16 Grade 3/4 non-hematologic drug-related AEs were rare, with fatigue reported in o1% of patients (Table 4) . Drug-related fluid retention or bleeding events were rare for patients with CML-AP on nilotinib therapy (Table 4 ). There was no reported drug-related pleural effusion or central nervous system bleeding. Only one patient had a drug-related grade 3/4 gastrointestinal bleeding event.
Myelosuppression events were predictable and generally easily managed. Grade 3/4 anemia, neutropenia and thrombocytopenia rates were 27%, 42% and 42%, respectively (Table 4) . Grade 3/4 biochemical abnormalities were infrequent with nilotinib treatment in patients with CML-AP (Table 5) . Grade 3/4 lipase elevation, hypophosphatemia or bilirubin elevation was reported in 18%, 15% or 9% of patients, respectively. The majority of biochemical abnormalities were mild to moderate in severity. With 24 months of follow-up, no patient had a post-baseline QTcF interval 4500 ms, and no episodes of torsades de pointes were reported. Overall, in this study, there was no cumulative risk of cardiac, hepatic or pancreatic events observed.
Discontinuation from nilotinib treatment due to drug-related AEs occurred in 10% of patients. Eight (6%) patients discontinued the treatment because of drug-related myelosuppression and one (o1%) discontinued the treatment because of drug-related pancreatitis. A total of 13 deaths have occurred, including 3 additional deaths since the last report; 16 2 deaths were due to progression and 1 due to cerebral hemorrhage. There were no reports of sudden deaths.
DISCUSSION
As imatinib has demonstrated efficacy in all phases of Ph þ CML, mutations in the BCR-ABL kinase associated with resistance to imatinib are more commonly found in patients with advancedphase disease. 8, 9 Furthermore, additional mechanisms of resistance, such as clonal evolution or amplification of BCR-ABL, may prevail in advanced stages of CML. In addition, the role of genetic instability, partially caused by BCR-ABL itself, needs to be considered.
Several phase 2 studies demonstrated significant survival improvements for patients with Ph þ CML-AP receiving 600 mg/ day imatinib compared with previous treatment options. 5,22 --24 However, responses were not sustained over the long term in the majority of these patients, and discontinuation rates in these studies were very high. For example, in one study that enrolled 181 patients with CML-AP, 32 patients (18%) remained on imatinib for 48 months, whereas 149 patients (82%) discontinued the study drug. 22 The most common reason for discontinuation was progression or lack of efficacy for 100 patients (67.1%). The small numbers of patients remaining on therapy after several years on these phase 2 studies demonstrate the need for alternative treatment options for CML patients with advanced disease.
Nilotinib was designed to bind to the DFG-out conformation of the ABL kinase domain, thus locking the enzyme in a catalytically inactive state. In comparison with imatinib, nilotinib is a more potent and selective inhibitor of BCR-ABL signaling. 10, 12 Nilotinib and another second-generation tyrosine kinase inhibitor, dasatinib (which inhibits ABL by binding to the active conformation of the enzyme 25 ), are currently approved for the treatment of patients with Ph þ CML-CP or -AP who are resistant or intolerant to prior therapies, including imatinib. Both nilotinib and dasatinib are effective against most BCR-ABL mutations known to confer resistance to imatinib, but the two drugs have distinct target selectivity profiles. 21 Approval of nilotinib was based on earlier results from the current phase 2 registration trial.
16,26 A 6-month follow-up data from patients with Ph þ CML-AP demonstrated rapid hematologic and cytogenetic responses in patients who were resistant or intolerant to prior imatinib, with rates of HR and MCyR of 47% and 29%, respectively. 16 The median time to HR and MCyR was 1 month (range, 0.8 --5.5) and 2 months (range, 0.9 --8.5), respectively.
The current 24-month follow-up data demonstrated that nilotinib therapy continues to be effective, with durable hematologic and cytogenetic responses in patients with CML-AP. The estimated overall survival of 70% at 24 months in this pretreated patient population suggests that nilotinib is effective and can provide favorable long-term outcomes for patients who have progressed to advanced phases of CML. It is noteworthy that response rates of patients on nilotinib therapy after imatinib failure are similar to those observed for patients receiving imatinib after non-tyrosine kinase inhibitor therapies in the pre-imatinib era.
Allogeneic stem cell transplant is an important salvage option for eligible patients who develop resistance to imatinib. Most commonly, nilotinib or dasatinib is given as second-line therapy in patients who develop resistance to imatinib, and SCT is reserved as a possible third-or fourth-line option in patients who fail both of these therapies. A recent retrospective analysis of 21 patients who had allogeneic SCT for Ph þ CML or Ph þ ALL showed that prior treatment with nilotinib or dasatinib did not adversely affect transplant outcomes. 27 Furthermore, as outcome after SCT is largely dependent on disease status at the time of transplantation, the high and durable rates of hematologic and cytogenetic responses seen here in nilotinib-treated patients and previously in dasatinib-treated patients 28 may lead to improved transplant outcomes in eligible patients pretreated with these drugs.
Overall, this study demonstrated that selectively targeting BCR-ABL with nilotinib is an important therapeutic option for patients who have progressed to advanced phase Ph þ CML. Nilotinib treatment resulted in a high overall survival rate at 2 years and was generally well tolerated in this heavily pretreated population for whom treatment options are limited.
